SRR23036890
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.580
- E2F_TARGETS+0.530
- MYC_TARGETS_V1+0.490
- G2M_CHECKPOINT+0.480
- MTORC1_SIGNALING+0.330
- OXIDATIVE_PHOSPHORYLATION+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.280
- DNA_REPAIR+0.260
- WNT_BETA_CATENIN_SIGNALING+0.160
- ANGIOGENESIS+0.100
Top 10 suppressed
- HYPOXIA-0.230
- APICAL_SURFACE-0.210
- COAGULATION-0.210
- HEME_METABOLISM-0.210
- INTERFERON_ALPHA_RESPONSE-0.210
- INTERFERON_GAMMA_RESPONSE-0.210
- NOTCH_SIGNALING-0.190
- KRAS_SIGNALING_DN-0.180
- ESTROGEN_RESPONSE_EARLY-0.170
- UV_RESPONSE_DN-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG922 | — | — | 0.843 |
| 2 | MDT-AP-0359 | Med | Medulloblastoma | 0.838 |
| 3 | SRR934893 | — | — | 0.830 |
| 4 | TCGA-39-5021-01A-01R-1443-07 | — | cohortSQ2 | 0.822 |
| 5 | TCGA-77-8144-01A-11R-2247-07 | — | cohortSQ1 | 0.820 |
| 6 | 293E6D35-8392-4C44-BC18-F917989516B0 | — | — | 0.816 |
| 7 | ERR2598070 | fetal | fetal | 0.815 |
| 8 | TCGA-85-6560-01A-11R-1820-07 | — | cohortMD1 | 0.810 |
| 9 | 0D600773-1B42-4F04-BCEA-39F658DF63F1 | — | — | 0.810 |
| 10 | TCGA-BB-A5HY-01A-11R-A28V-07 | — | — | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.080 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.060 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| APOPTOSIS | 0.040 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.040 | Idelalisib | — uncovered |